Burcon NutraScience (BU) Q3 2025 earnings summary

Executive summary

• Completed a CAD 9.4 million rights offering, strengthening the balance sheet and supporting growth initiatives.

• Secured operational control of a U.S.-based protein production facility through an alliance with ProMan, enabling full-scale commercialization.

• Launched new products including sunflower isolate protein, next-generation Peazazz pea protein, and Puratein canola protein for egg replacement, all generating strong market interest.

• Established a global R&D collaboration with Puratos to bring canola protein products to the baking industry.

Financial highlights

• Rights offering raised CAD 9.4 million, providing cash to support operations for at least two years.

• Generated $62,000 in quarterly revenue, up from $0 year-over-year, driven by protein isolate sales and contract research.

• Net loss narrowed to $1.8 million ($0.01 per share) from $2.0 million ($0.02 per share) year-over-year.

• Gross R&D expenses decreased to $0.7 million from $1.0 million year-over-year.

• No additional capital required for facility launch; ProMan covers facility purchase and equipment costs.

Outlook and guidance

• Full-scale commercial production at the new facility targeted for the first half of 2025.

• Path to cash flow positive projected for 2026, with margin expansion expected quarter-on-quarter.

• Initial sales in 2025 expected from pea protein, with sunflower protein driving growth in subsequent years.

• Focus on execution in 2025: facility closing, equipment installation, production trials, and recurring revenue.

• No major financings planned unless an opportunistic situation arises.